Compounds > etoposide
Page last updated: 2024-08-23

etoposide and Bare Lymphocyte Syndrome

etoposide has been researched along with Bare Lymphocyte Syndrome in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's4 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ishida, Y; Ishii, E; Kudo, K; Morimoto, A; Ohga, S; Suzuki, N1
Chen, DJ; Cooper, PK; Cowan, MJ; Pluth, JM; Wang, J; Yannone, SM1
Fichtner, I; Goan, SR; Herrmann, F; Just, U; Karawajew, L; Krause, KP; Schultze, W; von Harsdorf, S; von Schilling, C1
Cesano, A; Miller, EJ; Santoli, D; Torosian, MH; Visonneau, S1
Corbo, MV; Cotter, FE; Dean, NM; Fennell, DA; Monia, BP1
Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G1

Other Studies

6 other study(ies) available for etoposide and Bare Lymphocyte Syndrome

ArticleYear
Characteristics of hemophagocytic lymphohistiocytosis in neonates: a nationwide survey in Japan.
    The Journal of pediatrics, 2009, Volume: 155, Issue:2

    Topics: Acyclovir; Adrenal Cortex Hormones; Antineoplastic Agents, Phytogenic; Antiviral Agents; beta 2-Microglobulin; Consciousness Disorders; Cyclosporine; Erythema; Etoposide; Exanthema; Female; Fetal Distress; Fever; gamma-Globulins; Hematopoietic Stem Cell Transplantation; Herpes Simplex; Humans; Immunologic Factors; Immunosuppressive Agents; Infant, Newborn; Infant, Premature; Japan; L-Lactate Dehydrogenase; Leukocytosis; Lymphohistiocytosis, Hemophagocytic; Male; Ocular Motility Disorders; Plasma Exchange; Prognosis; Respiratory Distress Syndrome, Newborn; Seizures; Severe Combined Immunodeficiency

2009
Artemis deficiency confers a DNA double-strand break repair defect and Artemis phosphorylation status is altered by DNA damage and cell cycle progression.
    DNA repair, 2005, May-02, Volume: 4, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Etoposide; Fibroblasts; Gene Targeting; Histones; Humans; Mitosis; Nuclear Proteins; Phosphorylation; Radiation Tolerance; Radiation, Ionizing; Severe Combined Immunodeficiency; Skin

2005
The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis.
    Blood, 1995, Jul-01, Volume: 86, Issue:1

    Topics: Adult; Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Breast Neoplasms; Cell Line; Chimera; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Fibroblasts; Fluorouracil; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Interleukin-3; Lymphoid Tissue; Male; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Rats; Severe Combined Immunodeficiency; Testicular Neoplasms; Transplantation, Heterologous

1995
Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice.
    The American journal of pathology, 1998, Volume: 152, Issue:5

    Topics: Adenocarcinoma; Aged; Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Etoposide; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Polymerase Chain Reaction; Severe Combined Immunodeficiency; Transplantation, Heterologous; Tumor Cells, Cultured

1998
In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model.
    British journal of haematology, 2001, Volume: 112, Issue:3

    Topics: Animals; Apoptosis; bcl-X Protein; Caspase 3; Caspases; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Flow Cytometry; Genetic Therapy; Humans; Mice; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Severe Combined Immunodeficiency; Transplantation, Heterologous; Tumor Cells, Cultured

2001
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bone marrow transplantation, 2001, Volume: 28, Issue:8

    Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2001